Taxonomy
- Domain: Bacteria
- Phylum: Chlamydiae
- Class: Chlamydiae
- Order: Chlamydiales
- Family: Chlamydiaceae
- Genus: Chlamydia
- Species: Chlamydia caviae
Description
Chlamydia caviae is an obligate intracellular, gram‑negative bacterium belonging to the family Chlamydiaceae. Like other members of the genus, it possesses a biphasic developmental cycle comprising the infectious elementary body (EB) and the replicative reticulate body (RB). The organism lacks a classic peptidoglycan cell wall but retains a reduced peptidoglycan-like structure that is essential for cell division.
Genome
The genome of C. caviae is a circular chromosome approximately 1.1 Mbp in size, encoding around 900 proteins. Genomic analyses show high similarity to other Chlamydia species, particularly C. psittaci and C. abortus, with conserved loci for the major outer membrane protein (MOMP) and polymorphic membrane proteins (Pmps) that are implicated in host interaction and immune evasion.
Host range and pathology
The primary natural host for C. caviae is the domestic guinea pig (Cavia porcellus). Infection commonly manifests as conjunctivitis (often termed “inclusion conjunctivitis”) characterized by ocular discharge, swelling, and epithelial ulceration. In some cases, respiratory signs and systemic illness have been reported, though these are less frequent. Experimental infections have demonstrated that C. caviae can infect other rodent species under laboratory conditions, but natural transmission beyond guinea pigs is not well documented.
Epidemiology
Chlamydia caviae is endemic in breeding colonies and pet populations of guinea pigs. Transmission occurs primarily via direct contact with ocular or nasal secretions, as well as fomites contaminated with infectious elementary bodies. Outbreaks are more frequent in crowded housing conditions where stress and poor hygiene facilitate spread. There is limited evidence of zoonotic transmission to humans; no confirmed cases have been reported in the scientific literature.
Diagnosis
Laboratory confirmation of C. caviae infection utilizes several methods:
- Polymerase Chain Reaction (PCR): Species‑specific PCR assays targeting the 16S rRNA or ompA genes provide rapid and sensitive detection.
- Immunofluorescence microscopy: Direct staining of ocular smears with fluorescently labeled antibodies against Chlamydia spp. can visualize intracellular inclusions.
- Culture: Isolation in cell culture (e.g., McCoy or HeLa cells) is possible but requires biosafety level 2 facilities and is not routinely performed.
- Serology: Enzyme‑linked immunosorbent assays (ELISA) detecting anti‑Chlamydia antibodies may support diagnosis but lack species specificity.
Treatment and control
The antimicrobial agents of choice for C. caviae infections are tetracyclines, particularly doxycycline, administered systemically at 5 mg/kg body weight orally or intramuscularly once daily for 7–10 days. Alternative regimens include macrolides (e.g., azithromycin) when tetracyclines are contraindicated.
Control measures focus on hygiene and biosecurity:
- Regular cleaning and disinfection of cages with agents effective against elementary bodies (e.g., 1 % sodium hypochlorite).
- Quarantine of new arrivals for at least 4 weeks with health monitoring.
- Prompt isolation and treatment of clinically affected animals.
Research significance
Chlamydia caviae serves as a model organism for studying host‑specific adaptation within the Chlamydia genus. Comparative genomics between C. caviae and other chlamydial species contributes to understanding the evolution of pathogenicity determinants, especially those governing tissue tropism and immune evasion.
References
Due to the format constraints of this entry, specific literature citations are not listed. The information presented is derived from peer‑reviewed microbiology and veterinary infectious disease sources available up to the knowledge cutoff date.
